Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/physician-and-patient-barriers-to-breast-cancer-preventive-therapy-eZu5YXrqjW
References (62)
-
C. Kaplan, J. Haas, E. Perez-stable, Genevieve Jarlais, S. Gregorich (2005)
Factors affecting breast cancer risk reduction practices among California physicians.Preventive medicine, 41 1
-
T. Powles, R. Eeles, S. Ashley, D. Easton, Jenny Chang, M. Dowsett, A. Tidy, J. Viggers, J. Davey (1998)
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 352
-
S. Pruthi, R. Heisey, T. Bevers (2015)
Chemoprevention for Breast CancerAnnals of Surgical Oncology, 22
-
Arvind Bambhroliya, M. Chávez-MacGregor, A. Brewster (2015)
Barriers to the Use of Breast Cancer Risk Reduction Therapies.Journal of the National Comprehensive Cancer Network : JNCCN, 13 7
-
S. Day, T. Bevers (2015)
Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic: Donnelly LS, Evans DG, Wiseman J, et al (Univ Hosp of South Manchester, UK; Et al) Br J Cancer 110:1681-1687, 2014Breast Diseases: A Year Book Quarterly, 26
-
V. Moyer (2013)
Using Medications to Decrease the Risk for Breast Cancer in Women: Recommendations From the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 159
-
U. Veronesi, P. Maisonneuve, Alberto Costa, V. Sacchini, C. Maltoni, C. Robertson, N. Rotmensz, P. Boyle (1998)
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 352
-
C. Kaplan, Sue Kim, Sabrina Wong, G. Sawaya, J. Walsh, E. Perez-stable (2012)
Willingness to use tamoxifen to prevent breast cancer among diverse womenBreast Cancer Research and Treatment, 133
-
M. Gail, L. Brinton, D. Byar, D. Corle, S. Green, C. Schairer, J. Mulvihill (1989)
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.Journal of the National Cancer Institute, 81 24
-
P. Goss, J. Ingle, J. Alés‐Martínez, A. Cheung, R. Chlebowski, J. Wactawski‐Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin, E. Winquist, G. Sarto, J. Garber, C. Fabian, P. Pujol, E. Maunsell, P. Farmer, K. Gelmon, D. Tu, H. Richardson (2011)
Exemestane for breast-cancer prevention in postmenopausal women.The New England journal of medicine, 364 25
-
J. Corbelli, S. Borrero, R. Bonnema, M. McNamara, K. Kraemer, D. Rubio, Irina Karpov, M. McNeil (2014)
Use of the Gail model and breast cancer preventive therapy among three primary care specialties.Journal of women's health, 23 9
-
C. Holmberg, Erika Waters, K. Whitehouse, M. Daly, W. McCaskill-Stevens (2014)
My Lived Experiences Are More Important Than Your ProbabilitiesMedical Decision Making, 35
-
M. Cyrus-David, S. Strom (2001)
Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancerPsycho‐Oncology, 10
-
J. Cuzick, J. Forbes, R. Edwards, M. Baum, S. Cawthorn, A. Coates, A. Hamed, A. Howell, T. Powles (2002)
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialThe Lancet, 360
-
(2014)
A position paper outlining strategies needed to better predict risk and prevent breast cancer over the next 10 years -
C. Lerman, B. Rimer, B. Trock, A. Balshem, P. Engstrom (1990)
Factors associated with repeat adherence to breast cancer screening.Preventive medicine, 19 3
-
Samuel Smith, Samuel Smith, I. Šestak, Alice Forster, AH Partridge, Lucy Side, Michael Wolf, Rob Horne, Jane Wardle, Jack Cuzick (2015)
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisAnnals of Oncology, 27
-
M. Gail, J. Costantino, D. Pee, M. Bondy, L. Newman, M. Selvan, G. Anderson, K. Malone, P. Marchbanks, W. McCaskill-Stevens, S. Norman, M. Simon, R. Spirtas, G. Ursin, L. Bernstein (2007)
Projecting individualized absolute invasive breast cancer risk in African American women.Journal of the National Cancer Institute, 99 23
-
A. Howell, A. Anderson, R. Clarke, S. Duffy, G. Evans, M. Garcia-Closas, A. Gescher, T. Key, J. Saxton, M. Harvie (2014)
Risk determination and prevention of breast cancerBreast Cancer Research : BCR, 16
-
K. Strasser-Weippl, P. Goss (2013)
Suitable trial designs and cohorts for preventive breast cancer agentsNature Reviews Clinical Oncology, 10
-
S. Bober, L. Hoke, R. Duda, M. Regan, N. Tung (2004)
Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 24
-
Kathryn Martinez, A. Fagerlin, H. Witteman, C. Holmberg, S. Hawley (2016)
What Matters to Women When Making Decisions About Breast Cancer Chemoprevention?The Patient - Patient-Centered Outcomes Research, 9
-
particular interest, published recently, have been highlighted as: • Of importance -
V. Vogel, V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2010)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 3
-
J. Cuzick, J. Warwick, E. Pinney, R. Warren, S. Duffy (2004)
Tamoxifen and breast density in women at increased risk of breast cancer.Journal of the National Cancer Institute, 96 8
-
L. Donnelly, D. Evans, Julia Wiseman, J. Fox, R. Greenhalgh, J. Affen, Ilona Juraskova, P. Stavrinos, Sarah Dawe, J. Cuzick, A. Howell (2014)
Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinicBritish Journal of Cancer, 110
-
J. Cuzick, I. Šestak, J. Forbes, M. Dowsett, Jill Knox, S. Cawthorn, C. Saunders, N. Roche, R. Mansel, G. Minckwitz, B. Bonanni, T. Palva, A. Howell (2014)
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialThe Lancet, 383
-
E. Ozanne, J. Klemp, L. Esserman (2006)
Breast Cancer Risk Assessment and Prevention: A Framework for Shared Decision‐Making ConsultationsThe Breast Journal, 12
-
K. Crew (2015)
Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
-
B. Fisher, J. Costantino, D. Wickerham, C. Redmond, M. Kavanah, W. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-chiu, L. Ford, N. Wolmark (1999)
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.Journal of the National Cancer Institute, 90 18
-
R. Heisey, N. Pimlott, M. Clemons, Steven Cummings, Neil Drummond (2006)
Women's views on chemoprevention of breast cancer: qualitative study.Canadian family physician Medecin de famille canadien, 52
-
G. Colditz, K. Bohlke (2015)
Preventing breast cancer now by acting on what we already knowNPJ Breast Cancer, 1
-
A. Freedman, B. Graubard, Sowmya Rao, W. McCaskill-Stevens, R. Ballard-Barbash, M. Gail (2003)
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.Journal of the National Cancer Institute, 95 7
-
J. Cuzick, J. Warwick, E. Pinney, S. Duffy, S. Cawthorn, A. Howell, J. Forbes, R. Warren (2011)
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.Journal of the National Cancer Institute, 103 9
-
A. Brewster, N. Davidson, W. McCaskill-Stevens (2012)
Chemoprevention for breast cancer: overcoming barriers to treatment.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
-
D. Paterniti, J. Melnikow, J. Nuovo, Stuart Henderson, M. DeGregorio, M. Kuppermann, R. Nease (2005)
"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.Ethnicity & disease, 15 3
-
S. Day, T. Bevers (2015)
Quality of life in MAP.3 (mammary prevention 3): A randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerBreast Diseases: A Year Book Quarterly, 26
-
A. Decensi, M. Thorat, B. Bonanni, S. Smith, J. Cuzick (2015)
Barriers to preventive therapy for breast and other major cancers and strategies to improve uptakeecancermedicalscience, 9
-
G. Dite, R. MacInnis, A. Bickerstaffe, J. Dowty, R. Allman, C. Apicella, R. Milne, H. Tsimiklis, K. Phillips, G. Giles, M. Terry, M. Southey, J. Hopper (2015)
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family RegistryCancer Epidemiology, Biomarkers & Prevention, 25
-
R. Rahman, S. Pruthi (2012)
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy InactionCancers, 4
-
(2016)
National Cancer Institute Breast Cancer Risk Assessment Tool. Last updated 16 May 2011. www.cancer.gov/bcrisktool -
J. Cuzick, I. Šestak, S. Cawthorn, H. Hamed, K. Holli, A. Howell, J. Forbes (2015)
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialThe Lancet. Oncology, 16
-
A. Cheung, L. Tile, S. Cardew, S. Pruthi, J. Robbins, G. Tomlinson, M. Kapral, S. Khosla, S. Majumdar, M. Erlandson, J. Scher, Hanxian Hu, Alice Demaras, L. Lickley, L. Bordeleau, C. Elser, J. Ingle, H. Richardson, P. Goss (2012)
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.The Lancet. Oncology, 13 3
-
T. Salant, P. Ganschow, O. Olopade, D. Lauderdale (2006)
“Why take it if you don’t have anything?” breast cancer risk perceptions and prevention choices at a public hospitalJournal of General Internal Medicine, 21
-
R. Kukafka, Haeseung Yi, Tong Xiao, Parijatham Thomas, Alejandra Aguirre, C. Smalletz, Raven David, K. Crew (2015)
Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate WomenJournal of Medical Internet Research, 17
-
A. Fagerlin, B. Zikmund‐Fisher, Dylan Smith, V. Nair, Holly Derry, J. McClure, Sarah Greene, A. Stark, S. Alford, P. Lantz, D. Hayes, Cheryl Wiese, S. Zweig, R. Pitsch, Aleksandra Janković, P. Ubel (2010)
Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aidBreast Cancer Research and Treatment, 119
-
S. Sabatino, E. McCarthy, R. Phillips, R. Burns (2007)
Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers.Cancer detection and prevention, 31 5
-
Lindsey Karavites, Subhashini Allu, S. Khan, K. Kaiser (2015)
Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group studyBMC Cancer, 15
-
(2016)
An excellent overview of national evidence-based guidelines for breast cancer prevention -
V. Moyer (2013)
Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 159
-
B. Rockhill, D. Spiegelman, C. Byrne, D. Hunter, G. Colditz (2001)
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.Journal of the National Cancer Institute, 93 5
-
J. Carroll, T. Makuwaza, D. Manca, N. Sopcak, J. Permaul, M. O’Brien, R. Heisey, E. Eisenhauer, J. Easley, M. Krzyzanowska, B. Miedema, S. Pruthi, C. Sawka, Nancy Schneider, J. Sussman, R. Urquhart, C. Versaevel, E. Grunfeld (2016)
Primary care providers' experiences with and perceptions of personalized genomic medicine.Canadian family physician Medecin de famille canadien, 62 10
-
M. Lazzeroni, D. Serrano, B. Dunn, B. Heckman-Stoddard, O. Lee, S. Khan, A. Decensi (2012)
Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drugBreast Cancer Research : BCR, 14
-
(2015)
A visual model is presented to help primary care providers identify cohorts suitable for preventive therapies -
J. Costantino, M. Gail, D. Pee, S. Anderson, C. Redmond, J. Benichou, H. Wieand (1999)
Validation studies for models projecting the risk of invasive and total breast cancer incidence.Journal of the National Cancer Institute, 91 18
-
M. Ropka, Jess Keim, J. Philbrick (2010)
Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18
-
(2016)
Curr Breast Cancer Rep -
M. Harvie, A. Howell, D. Evans (2015)
Can diet and lifestyle prevent breast cancer: what is the evidence?American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
-
S. Pruthi, R. Heisey, T. Bevers (2015)
Personalized Assessment and Management of Women at Risk for Breast Cancer in North AmericaWomen's Health, 11
-
E. Maunsell, P. Goss, R. Chlebowski, J. Ingle, J. Alés‐Martínez, G. Sarto, C. Fabian, P. Pujol, A. Ruiz, A. Cooke, S. Hendrix, Debra Thayer, K. Rowland, P. Dubé, S. Spadafora, S. Pruthi, L. Lickley, S. Ellard, A. Cheung, J. Wactawski‐Wende, K. Gelmon, D. Johnston, Andrea Hiltz, M. Brundage, J. Pater, D. Tu, H. Richardson (2014)
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 14
-
J. Cuzick, I. Šestak, M. Thorat (2015)
Impact of preventive therapy on the risk of breast cancer among women with benign breast diseaseBreast (Edinburgh, Scotland), 24
-
J. Litton (2012)
Exemestane for breast-cancer prevention in postmenopausal womenBreast Diseases: A Year Book Quarterly, 23
- Publisher
- Springer Journals
- Copyright
- Copyright © 2016 by The Author(s)
- Subject
- Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-016-0216-5
- Publisher site
- See Article on Publisher Site
Abstract
The uptake of selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) for the primary prevention of breast cancer is low, despite their proven efficacy in several randomized clinical trials. This review summarizes the latest data on physicians’ and women’s barriers to breast cancer preventive therapy. Physicians’ challenges include: identifying suitable candidates for preventive therapy, inadequate training and confidence in risk assessment and counselling, insufficient knowledge of risk-reducing medications, and lack of time. High-risk women fear medication side effects, and they often weigh experiences of others more heavily than statistical probabilities to guide their decision-making. Despite decision aid interventions to help women make an informed decision, acceptance of preventive therapy will remain low until: risk/benefit profiles are more favorable, physicians are better educated and skilled in having these discussions, and suitable biomarkers to monitor drug efficacy and better clinical risk prediction models to assess true individual risk are available.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Jun 13, 2016